In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link GLP 1s effectiveness at blood pressure control on par with traditional anti hypertensives, tracks well with % weight loss. In someone with hypertension due to their underlying obesity, why not Michael Weintraub, MD Mazdutide vs Tirzepatide vs Semaglutide: Comparative Efficacy Ney Carter Borges MD M.Sc. Ph.D FESC,FACC,FAHA,FACP. posted on the topic LinkedIn Cagrilintide 10mg Peptides for Research 99% Purity Certified